Glaucoma Treatment Market Size - By Disease Type (Open Angle Glaucoma, Angle Closure Glaucoma), Drug Class (Prostaglandin Analogs, Beta Blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors), Distribution Channel & Forecast, 2022 - 2028

Glaucoma Treatment Market Size - By Disease Type (Open Angle Glaucoma, Angle Closure Glaucoma), Drug Class (Prostaglandin Analogs, Beta Blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors), Distribution Channel & Forecast, 2022 - 2028

Glaucoma Treatment Market Size

Glaucoma Treatment Market size exceeded USD 5.5 billion in 2021 and is expected to witness over 3.2% CAGR from 2022 to 2028. Rising prevalence of glaucoma diseases and growing demand for advanced therapeutic interventions are some of the major factors that facilitate the market growth. According to the World Glaucoma Association, around 76 million people were suffering from glaucoma in 2020.
 

Moreover, primary open angle glaucoma (POAG) is the predominant type of glaucoma in the population. In 2020, more than 57.5 million people worldwide were affected by POAG with a global prevalence of 2.2%. Thus, rising glaucoma disease burden is anticipated to offer lucrative growth opportunities in the market. Furthermore, the growing geriatric population that is prone to age-related diseases is another prominent factor that will accelerate glaucoma treatment industry growth over the estimated time period.
 

The COVID-19 pandemic had slightly negative impact on the sales of glaucoma treatment market owing to the imposition of preventive lockdown in several economies. Additionally, prioritization and mobilization of all resources to COVID 19 patients due to shortage of healthcare infrastructure. Also, numerous ophthalmology departments were converted into COVID-19 wards which restricted the follow-ups of glaucoma patients. Furthermore, fewer patient visits to the clinical settings owing to fear of infection among older adults have resulted in lessened demand for market. However, adoption of telemedicine platforms during pandemic helped the patients to get access to the treatment on time which impelled the overall industry growth.
 

Glaucoma is a disorder of progressive optic neuropathies that is caused by degeneration of retinal nerve fiber layers and retinal ganglion cells that may lead to changes in the optical nerve head. The major risk factor is that high intraocular pressure (IOP) can damage the optic nerve and continued damage to this structure may lead to irreversible visual field defects, visual impairment, and blindness. Glaucoma is the leading cause of irreversible blindness across the world. Risk factors include gender, race, myopia, family history, genetics, age and frailty, vasospasm, smoking, systemic hypotension and hypertension, obstructive sleep apnea syndrome, migraine, consumption of steroids, and most significantly, increased IOP. These factors will spur the demand for glaucoma treatment market.
 

Recent advancements in therapeutic interventions will fuel the market momentum

Continuous technological advancements in ophthalmology field are one of the major factors fuelling the glaucoma treatment market outlook. Increasing demand for advanced surgical procedures will propel industry growth potential. Moreover, advancements in optometric care such as medical imaging, selective laser trabeculoplasty (SLT), optical coherence tomography (OCT), visual fields, microinvasive glaucoma surgery (MIGS) and progression analysis software will boost patient preference. Additionally, integration of laser treatments as first-line therapy along with medication to treat glaucoma will proliferate the market size.
 

Glaucoma Treatment Market Analysis

Based on disease type, the glaucoma treatment market is segmented as open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment accounted for more than USD 4.5 billion in 2021. The growth of the segment is attributed to high prevalence of open angle glaucoma worldwide. For instance, as per the British Journal of Ophthalmology, POAG is the most common type of glaucoma in the UK that affects 2% of people older than 40 years and 10% of people older than 75 years. Moreover, growing usage of hypotensive drops to reduce intra ocular pressure is contributing to the overall segmental expansion.
 

Based on drug class, the glaucoma treatment market is categorized into prostaglandin analogs, beta blockers, adrenergic agonists, carbonic anhydrase inhibitors, and others. Prostaglandin analogs segment held more than 30% market share in 2021 owing to increasing accessibility and availability of ophthalmic medications worldwide. High adoption of prostaglandin analogs to reduce intraocular pressure with several benefits including once daily dosing effectivity, the enhanced recovery rate in glaucoma treatment will spur segmental demand. Furthermore, increasing demand for prostaglandin drugs in combination therapy is anticipated to offer enormous growth opportunities in the segment. Also, growing awareness about early glaucoma treatment along with rising patient population undergoing early glaucoma disease diagnosis will further boost the overall market statistics.
 

Based on distribution channel, the glaucoma treatment market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment garnered more than USD 3 billion in 2021. The segment is predicted to grow substantially over the analysis timeframe. The substantial growth is owing to high availability of products in settings for several types of glaucoma treatment. Also, patient preference towards hospital pharmacy for prescribed products helps in revenue generation. Furthermore, reimbursement policies and insurance cover provided for drug purchase in hospital settings will boost its market forecasts.
 

North America glaucoma treatment market is poised to grow at 3.4% CAGR over projected timeline. Increasing prevalence of several types of glaucoma in the region will accelerate the demand for glaucoma treatments. Growing awareness related to eye care and associated diagnosis and treatments will spur market size. Moreover, strong presence of key market players in the region that are involved in new drug development and product approvals will strengthen regional industry growth.
 

Glaucoma Treatment Market Share

Some of the notable business players operating in the glaucoma treatment market include

• Merck & Co., Inc.
• Novartis AG
• AERIE Pharmaceuticals, Inc.
• Akorn operating company LLC
• Cipla Inc
•  AbbVie
• Bausch & Lomb Incorporated
• Inotek Pharmaceuticals
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Santen Pharmaceutical Co., Ltd.

These industry players are implementing several growth strategies such as collaboration, partnership, acquisition & merger and product launch to gain competitive edge over others in glaucoma treatment industry.
 

Some of the recent industry developments

• In March 2021, Teva Pharmaceuticals launched first generic version of AZOPT (brinzolamide ophthalmic suspension) 1% to treat open angle glaucoma and ocular hypertension in the U.S. This has strengthened company’s product portfolio.
   
• In December 2021, Aerie Pharmaceuticals, Inc. collaborated with Santen Pharmaceuticals to develop and commercialize Rhopressa/Rhokiinsa and Rocklatan/Roclanda for glaucoma treatment in Europe, India, China, Oceania countries and parts of Latin America. These will enhance the market position of both firms in these regions.
   

The glaucoma treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028, for the following segments

Click here to Buy Section of this Report

By Disease Type

• Open angle glaucoma
• Angle closure glaucoma
• Others

By Drug Class

• Prostaglandin analogs
• Beta blockers
• Adrenergic agonists
• Carbonic anhydrase inhibitors
• Others

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online Pharmacy

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE